NL1027109C2 - Verbinding en gebruik bij behandeling. - Google Patents

Verbinding en gebruik bij behandeling. Download PDF

Info

Publication number
NL1027109C2
NL1027109C2 NL1027109A NL1027109A NL1027109C2 NL 1027109 C2 NL1027109 C2 NL 1027109C2 NL 1027109 A NL1027109 A NL 1027109A NL 1027109 A NL1027109 A NL 1027109A NL 1027109 C2 NL1027109 C2 NL 1027109C2
Authority
NL
Netherlands
Prior art keywords
pharmaceutically acceptable
compound
alpha
treatment
hydroxy
Prior art date
Application number
NL1027109A
Other languages
English (en)
Dutch (nl)
Other versions
NL1027109A1 (nl
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of NL1027109A1 publication Critical patent/NL1027109A1/nl
Application granted granted Critical
Publication of NL1027109C2 publication Critical patent/NL1027109C2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NL1027109A 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling. NL1027109C2 (nl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0322395 2003-09-24
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0325598 2003-11-03
GB0416876 2004-07-29
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
NL1027109A1 NL1027109A1 (nl) 2005-03-29
NL1027109C2 true NL1027109C2 (nl) 2005-05-03

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1027109A NL1027109C2 (nl) 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling.

Country Status (12)

Country Link
EP (1) EP1673096A1 (zh)
JP (2) JP2007506699A (zh)
CN (1) CN100488511C (zh)
BE (1) BE1016292A3 (zh)
BR (1) BRPI0404050A (zh)
CH (1) CH698144B1 (zh)
EA (1) EA010240B1 (zh)
FR (1) FR2859910B1 (zh)
HK (1) HK1085373A1 (zh)
NL (1) NL1027109C2 (zh)
NZ (1) NZ535531A (zh)
WO (1) WO2005027923A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027052A (zh) * 2004-10-05 2007-08-29 橘生药品工业株式会社 用于伴下尿路梗阻的集尿障碍的预防和/或治疗剂
ES2378240T3 (es) * 2004-10-06 2012-04-10 Kissei Pharmaceutical Co., Ltd. Composición medicinal para evitar la transición al tratamiento operatorio de la hipertrofia prostática
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6100294A (en) * 1997-05-16 2000-08-08 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH) 3-epi-vitamin D3 compounds and uses thereof
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANON: "BioXell commences phase II trial of BXL - 628", DRUG NEWS & PERSPECTIVES, (MAR 2003) VOL. 16, NO. 2, PP. 122-122. PUBLISHER: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0214-0934., March 2003 (2003-03-01), XP001205124 *
BRANDL MICHAEL ET AL: "Chemical reactivity of Ro-26-9228, 1alpha-fluoro-25-hydroxy-16,23E-di ene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 10, October 2003 (2003-10-01), pages 1981 - 1989, XP002315528, ISSN: 0022-3549 *
CRESCIOLI C ET AL: "Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 591 - 603, XP009043025, ISSN: 0804-4643 *
http://www3.interscience.wiley.com/cgi-bin/abstract/104550629/ABSTRACT, Published Online 30 Jul 2003 *
MEALY N E: "BXL-628", DRUGS OF THE FUTURE 2004 SPAIN, vol. 29, no. 6, 2004, pages 629, XP009043214, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
JP2009035559A (ja) 2009-02-19
EP1673096A1 (en) 2006-06-28
JP2007506699A (ja) 2007-03-22
HK1085373A1 (en) 2006-08-25
NZ535531A (en) 2006-03-31
FR2859910B1 (fr) 2006-04-28
EA200401100A1 (ru) 2005-04-28
BE1016292A3 (nl) 2006-07-04
CN100488511C (zh) 2009-05-20
BRPI0404050A (pt) 2005-06-14
NL1027109A1 (nl) 2005-03-29
EA010240B1 (ru) 2008-06-30
CN1615891A (zh) 2005-05-18
FR2859910A1 (fr) 2005-03-25
CH698144B1 (fr) 2009-05-29
WO2005027923A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
US9877932B2 (en) Treatment of prostate carcinoma
JP6548641B2 (ja) 転移性前立腺癌の治療
US11690812B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
US10780063B2 (en) Method for the treatment or prevention of lower urinary tract symptoms
Taylor et al. 17β-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss
ES2643318T3 (es) Composiciones y métodos para suprimir la proliferación endometrial
US20080207769A1 (en) Method for treating benign prostatic hyperplasia
JP2009035559A (ja) 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用
Iacono et al. RETRACTED ARTICLE: Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
Wang et al. Androgen replacement therapy, risks and benefits
JP2021519799A (ja) 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
US9814730B2 (en) Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
WO1998024448A1 (en) METHOD OF PREVENTING NEURODEGENERATION AND COGNITIVE DYSFUNCTION USING 17α-DIHYDROEQUILENIN
CN116139140A (zh) 一种化合物在治疗糖皮质激素不良反应中的用途
GB2407499A (en) Compound and use in treatment

Legal Events

Date Code Title Description
AD1B A search report has been drawn up
PD2B A search report has been drawn up
V1 Lapsed because of non-payment of the annual fee

Effective date: 20110401